Connectus Wealth, LLC Vertex Pharmaceuticals Inc Transaction History

Connectus Wealth, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $1.27 Million - $1.52 Million	3,706 Added 26.0%	17,959 $7.31 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $1.39 Million - $1.49 Million	4,118 Added 40.63%	14,253 $4.96 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $173,559 - $194,254	552 Added 5.76%	10,135 $3.57 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $32,571 - $37,156	115 Added 1.21%	9,583 $3.02 Million
Q4 2022 Feb 07, 2023	BUY	$285.76 - $321.48 $24,575 - $27,647	86 Added 0.92%	9,468 $2.73 Million
Q3 2022 Nov 10, 2022	BUY	$273.83 - $305.53 $257,947 - $287,809	942 Added 11.16%	9,382 $2.72 Million
Q2 2022 Aug 08, 2022	BUY	$234.96 - $292.55 $1.98 Million - $2.47 Million	8,440 New	8,440 $2.38 Million
Q1 2022 May 06, 2022	SELL	$221.42 - $260.97 $715,629 - $843,455	-3,232 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$177.01 - $223.45 $572,096 - $722,190	3,232 New	3,232 $710,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Connectus Wealth, LLC, based on Form 13F filings with the SEC.

Stay updated on Connectus Wealth, LLC with notifications on news.